Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL763637 | 0.97 | SYK (0.94) | SYK | |
| SCHEMBL736082 | 0.96 | SYK (1.00) | SYK | |
| SCHEMBL2387225 | 0.95 | SYK (0.94) | SYK | |
| SCHEMBL737173 | 0.92 | SYK (1.00) | SYK | |
| SCHEMBL22278302 | 0.92 | SYK (0.98) | SYK | |
| SCHEMBL735011 | 0.92 | SYK (1.00) | SYK | |
| SCHEMBL738055 | 0.91 | SYK (1.00) | SYK | |
| SCHEMBL737987 | 0.90 | SYK (1.00) | SYK | |
| SCHEMBL738342 | 0.90 | SYK (1.00) | SYK | |
| SCHEMBL737310 | 0.89 | SYK (1.00) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11414410-B2 | Inhibitors of protein kinases | ALEXION PHARMACEUTICALS, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| US-20200239458-A1 | INHIBITORS OF PROTEIN KINASES | ALEXION PHARMACEUTICALS, INC. | 2020-07-30 | — | — | US | disclosed |
| US-20200239458-A1 | INHIBITORS OF PROTEIN KINASES | ALEXION PHARMACEUTICALS, INC. | 2020-07-30 | — | — | US | disclosed |
| US-20180186783-A1 | INHIBITORS OF PROTEIN KINASES | ALEXION PHARMACEUTICALS, INC. | 2018-07-05 | — | — | US | disclosed |
| US-20180186783-A1 | INHIBITORS OF PROTEIN KINASES | ALEXION PHARMACEUTICALS, INC. | 2018-07-05 | — | — | US | disclosed |
| US-20180186783-A1 | INHIBITORS OF PROTEIN KINASES | ALEXION PHARMACEUTICALS, INC. | 2018-07-05 | — | — | US | disclosed |
| US-9868729-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868729-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868729-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20150094298-A1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. | 2015-04-02 | — | — | US | disclosed |
| US-20120129867-A1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-8138339-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138339-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138339-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| EP-2321283-A1 | 2, 6-DIAMINO-PYRIMIDIN- 5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS | Portola Pharmaceuticals, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20090318407-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090318407-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090318407-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2009145856-A1 | 2, 6-DIAMINO-PYRIMIDIN- 5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | WO | disclosed |
| WO-2009145856-A1 | 2, 6-DIAMINO-PYRIMIDIN- 5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318407-A1 | Inhibitors of protein kinases | SYK, BTK, JAK1 | SYK 1/4885 |
| US-20120129867-A1 | INHIBITORS OF PROTEIN KINASES | SYK, BTK, JAK1 | SYK 1/4885 |
| US-20200239458-A1 | INHIBITORS OF PROTEIN KINASES | SYK, BTK, JAK1 | SYK 1/4885 |
| US-20180186783-A1 | INHIBITORS OF PROTEIN KINASES | SYK, BTK, JAK1 | SYK 1/4885 |
| US-11414410-B2 | Inhibitors of protein kinases | MAP3K1, MAP3K20, MAP3K2 | SYK 409/4885 |
| US-20150094298-A1 | INHIBITORS OF PROTEIN KINASES | SYK, BTK, JAK1 | SYK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.